EE200100553A - Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks - Google Patents

Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks

Info

Publication number
EE200100553A
EE200100553A EEP200100553A EEP200100553A EE200100553A EE 200100553 A EE200100553 A EE 200100553A EE P200100553 A EEP200100553 A EE P200100553A EE P200100553 A EEP200100553 A EE P200100553A EE 200100553 A EE200100553 A EE 200100553A
Authority
EE
Estonia
Prior art keywords
disorders
saredutant
medicament
prevention
manufacture
Prior art date
Application number
EEP200100553A
Other languages
English (en)
Inventor
Emonds-Alt Xavier
Soubrie Philippe
Steinberg R�gis
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200100553A publication Critical patent/EE200100553A/et
Publication of EE05211B1 publication Critical patent/EE05211B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200100553A 1999-04-27 2000-04-25 Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks EE05211B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
PCT/FR2000/001084 WO2000064423A2 (fr) 1999-04-27 2000-04-25 Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression

Publications (2)

Publication Number Publication Date
EE200100553A true EE200100553A (et) 2003-02-17
EE05211B1 EE05211B1 (et) 2009-10-15

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100553A EE05211B1 (et) 1999-04-27 2000-04-25 Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks

Country Status (32)

Country Link
US (3) US6573281B1 (et)
EP (1) EP1173179B1 (et)
JP (1) JP2002542281A (et)
KR (1) KR20020001850A (et)
CN (1) CN1172669C (et)
AR (1) AR023597A1 (et)
AT (1) ATE234617T1 (et)
AU (1) AU764304B2 (et)
BG (1) BG65472B1 (et)
BR (1) BR0010006A (et)
CA (1) CA2370834C (et)
CZ (1) CZ294904B6 (et)
DE (1) DE60001725T2 (et)
DK (1) DK1173179T3 (et)
EE (1) EE05211B1 (et)
ES (1) ES2193065T3 (et)
FR (1) FR2792835B3 (et)
HU (1) HUP0200969A3 (et)
IL (1) IL145269A0 (et)
MX (1) MXPA01010904A (et)
NO (1) NO20015228L (et)
NZ (1) NZ513851A (et)
PL (1) PL196479B1 (et)
PT (1) PT1173179E (et)
RU (1) RU2238726C2 (et)
SI (1) SI1173179T1 (et)
SK (1) SK285459B6 (et)
TR (1) TR200102512T2 (et)
TW (1) TWI225399B (et)
UA (1) UA69441C2 (et)
WO (1) WO2000064423A2 (et)
ZA (1) ZA200107143B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
JP2003530381A (ja) * 2000-04-06 2003-10-14 アストラゼネカ・アクチエボラーグ 化合物
ATE400563T1 (de) * 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
KR101174980B1 (ko) * 2007-09-14 2012-08-17 에프. 호프만-라 로슈 아게 Ｎｋ３ 수용체 길항제로서의 피페리딘 유도체
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
US20030176462A1 (en) 2003-09-18
US6573281B1 (en) 2003-06-03
UA69441C2 (uk) 2004-09-15
CZ294904B6 (cs) 2005-04-13
CA2370834A1 (en) 2000-11-02
KR20020001850A (ko) 2002-01-09
SK285459B6 (sk) 2007-02-01
PL351922A1 (en) 2003-06-30
ATE234617T1 (de) 2003-04-15
EE05211B1 (et) 2009-10-15
TWI225399B (en) 2004-12-21
US7390823B2 (en) 2008-06-24
EP1173179B1 (fr) 2003-03-19
CA2370834C (en) 2007-09-25
SK15472001A3 (sk) 2002-03-05
BR0010006A (pt) 2002-01-15
HK1041821A1 (en) 2002-07-26
WO2000064423A2 (fr) 2000-11-02
EP1173179A2 (fr) 2002-01-23
DE60001725D1 (de) 2003-04-24
RU2238726C2 (ru) 2004-10-27
PT1173179E (pt) 2003-06-30
US20080227818A1 (en) 2008-09-18
ES2193065T3 (es) 2003-11-01
NO20015228D0 (no) 2001-10-25
AR023597A1 (es) 2002-09-04
DK1173179T3 (da) 2003-07-14
NO20015228L (no) 2001-12-21
AU4303400A (en) 2000-11-10
FR2792835A1 (fr) 2000-11-03
IL145269A0 (en) 2002-06-30
CZ20013812A3 (cs) 2002-02-13
BG65472B1 (bg) 2008-09-30
CN1348371A (zh) 2002-05-08
HUP0200969A3 (en) 2004-03-01
NZ513851A (en) 2003-04-29
DE60001725T2 (de) 2004-02-05
JP2002542281A (ja) 2002-12-10
ZA200107143B (en) 2002-10-30
SI1173179T1 (en) 2003-06-30
MXPA01010904A (es) 2002-06-21
FR2792835B3 (fr) 2001-05-25
TR200102512T2 (tr) 2002-04-22
WO2000064423A3 (fr) 2001-04-19
PL196479B1 (pl) 2008-01-31
CN1172669C (zh) 2004-10-27
BG105962A (en) 2002-05-31
AU764304B2 (en) 2003-08-14
HUP0200969A2 (hu) 2002-07-29

Similar Documents

Publication Publication Date Title
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
PL358306A1 (en) Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
JP2002542281A5 (et)
PL367214A1 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
RU2001124802A (ru) Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL356001A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
BR0000486A (pt) Antagonistas do neuropeptìdeo y
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
ZA200308631B (en) 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110425